Daniel A Pollyea

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Utility of influenza vaccination for oncology patients
    Daniel A Pollyea
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Clin Oncol 28:2481-90. 2010
  2. doi request reprint Acute myeloid leukaemia in the elderly: a review
    Daniel A Pollyea
    Divisions of Hematology and Oncology, Department of Internal Medicine, University Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Br J Haematol 152:524-42. 2011
  3. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
  4. doi request reprint Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience
    Holbrook E Kohrt
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA 94305, USA
    Am J Hematol 85:877-81. 2010

Detail Information

Publications4

  1. doi request reprint Utility of influenza vaccination for oncology patients
    Daniel A Pollyea
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Clin Oncol 28:2481-90. 2010
    ....
  2. doi request reprint Acute myeloid leukaemia in the elderly: a review
    Daniel A Pollyea
    Divisions of Hematology and Oncology, Department of Internal Medicine, University Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Br J Haematol 152:524-42. 2011
    ..Elderly patients, with their narrow therapeutic window, are well positioned to derive a benefit from these novel agents, and therefore, despite a difficult past, there are reasons to be optimistic about the future of elderly AML...
  3. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
    ..In conclusion, a sequential combination of azacitidine plus lenalidomide has clinical activity in older patients with acute myeloid leukemia, and further studies of this combination are underway...
  4. doi request reprint Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience
    Holbrook E Kohrt
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA 94305, USA
    Am J Hematol 85:877-81. 2010
    ..3 and 7.6 months, P = 0.36). Despite risk stratification by the European Prognostic Index, our series demonstrates inferior rates of response and survival, illustrating the limited activity of this regimen in our cohort...